COMMUNIQUÉS West-GlobeNewswire

BrainStorm Issues a Statement to Patients and Shareholders

19/02/2019 - 14:06

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in [...]

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

19/02/2019 - 14:02

Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , a clinical stage [...]

Cabaletta Bio Appoints Experienced Financial Executive, Richard Henriques, to its Board of Directors

19/02/2019 - 14:00

RADNOR, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, announced today the [...]

Voyager Therapeutics to Present at Upcoming Investor Conferences

19/02/2019 - 14:00

CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today [...]

GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease

19/02/2019 - 14:00

—The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle Cell Disease— —GBT Will Fund Proposals [...]

Imagin Medical to Report First Fiscal Quarter 2019 Financial Results on February 27, 2019 – Conference Call to Follow

19/02/2019 - 14:00

VANCOUVER, British Columbia and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the [...]

VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26

19/02/2019 - 14:00

TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2 for inflammatory and [...]

Aucta Pharmaceuticals and Oakrum Pharma Announce Product Development and Commercialization Partnership

19/02/2019 - 14:00

NORTH BRUNSWICK, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aucta Pharmaceuticals, Inc. (Aucta) announced today that it has entered into an agreement with Oakrum Pharma, LLC (Oakrum) to develop and manufacture four [...]

Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

19/02/2019 - 14:00

Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq [...]

Dova Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

19/02/2019 - 14:00

DURHAM, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 8 th [...]

Assertio Therapeutics Announces Appointment of Heather L. Mason to Board of Directors

19/02/2019 - 14:00

LAKE FOREST, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Heather L. Mason has been appointed to the Company’s Board of Directors. Ms. Mason is a former [...]

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

19/02/2019 - 14:00

Encouraging Preliminary Signs of Efficacy, Including One Complete Response, Observed in Patients With Advanced Bladder Cancer Who Have Progressed on Multiple Prior Treatments Including Immunotherapy and Gemcitabine [...]

AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference

19/02/2019 - 14:00

WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted Myles, chief financial [...]

Spectral Announces Approval of Tigris Trial by the US FDA

19/02/2019 - 14:00

TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a [...]

electroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies

19/02/2019 - 14:00

BASKING RIDGE, N.J. and NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc . (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a patient education initiative in partnership [...]

La société Medexus Pharmaceuticals organise une conférence téléphonique sur le troisième trimestre de l’exercice 2019

19/02/2019 - 14:00

Elle retient les services de Crescendo Communications pour les services de relations avec les investisseurs La conférence téléphonique aura lieu à 16 h 30 heure de l’Est le lundi 25 février 2019 MONTRÉAL, 19 févr. 2019 [...]

Immunomedics to Report Results for the Quarter and Six Months Ended December 31, 2018 and Host Conference Call and Webcast on February 25, 2019

19/02/2019 - 14:00

MORRIS PLAINS, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today [...]

CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

19/02/2019 - 14:00

Total of 181 subjects enrolled with elevated liver fat and biopsy-confirmed NASH Over 80 % of subjects had baseline F2 or F3 stage fibrosis Subjects were randomized to seladelpar 10 mg, 20 mg or 50 mg or placebo Twelve- [...]

Private Placement of $366,666

19/02/2019 - 14:00

MONTRÉAL, Feb. 19, 2019 (GLOBE NEWSWIRE) -- TERRANUEVA CORPORATION (“Terranueva” or the “Company”) is pleased to announce that it has completed a private placement for an aggregate amount of $366,666 in common shares at [...]